Acadia Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
Key Terms
parkinson’s disease psychosismedical
A complication of Parkinson’s disease in which people experience hallucinations, false beliefs, or confused thinking that arise from the illness itself or as a side effect of its treatments. It matters to investors because it creates a distinct medical need and market for safer therapies, influences clinical trial design and regulatory review, and can affect healthcare costs and drug sales; think of it as a car’s warning lights misfiring, prompting demand for better, more reliable fixes.
rett syndromemedical
A rare genetic disorder that disrupts normal brain development in young children, most commonly girls, leading to slowed growth, loss of purposeful hand use, repetitive hand movements, motor problems, speech loss, and cognitive and breathing irregularities. Investors watch it because its severity and few treatment options create clear medical need and potential markets for therapies; think of it as a broken traffic signal in the brain that, if fixed, could restore many downstream functions.
alzheimer’s disease psychosismedical
A set of hallucinations, false beliefs or related behavioral disturbances that occur in some people with Alzheimer’s disease, making memory loss and confusion worse and often increasing caregiving needs. It matters to investors because these symptoms represent a clear unmet medical need that drives clinical trials, regulatory review and potential drug sales; a treatment that safely reduces psychosis can change patient care patterns, lower long‑term costs and create significant market value, like fixing a major complication that suddenly makes a chronic problem much harder to manage.
lewy body dementia psychosismedical
Lewy body dementia psychosis is the set of hallucinations, false beliefs and severe confusion that can occur in people with Lewy body dementia, a progressive brain disorder marked by abnormal protein clumps in nerve cells. It matters to investors because these behavioral symptoms shape the need for treatments, influence clinical trial design and regulatory approval, and drive long‑term care costs and market size—like a key product feature that determines demand and safety scrutiny.
webcasttechnical
A webcast is a live or recorded online event where people watch or listen to presentations, announcements, or performances through the internet. It’s like a TV broadcast but over the internet, allowing viewers from anywhere to tune in in real time or later. Webcasts are important because they let companies share information quickly and widely with audiences around the world.
fda-approvedregulatory
FDA-approved means a medical product, drug, device or treatment has passed the U.S. Food and Drug Administration’s review for safety and effectiveness for a specific use. Think of it like a formal safety and performance seal that allows the product to be marketed for that purpose in the U.S.; for investors, approval reduces regulatory uncertainty, enables sales and reimbursement pathways, and can materially affect a company’s revenue prospects and valuation.
SAN DIEGO--(BUSINESS WIRE)--
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the 44thAnnual J.P. Morgan Healthcare Conference in San Francisco, CA. Catherine Owen Adams, Chief Executive Officer will represent the company in a session scheduled on Tuesday, January 13, 2026, at 9:45 a.m. Pacific Time / 12:45 p.m. Eastern Time.
A live webcast of Acadia’s presentation will be accessible on the company’s website, acadia.com, under the investors section and an archived recording will be available on the website for approximately one month following the presentation.
About Acadia Pharmaceuticals
Acadia is committed to turning scientific promise into meaningful innovation that makes the difference for underserved neurological and rare disease communities around the world. Our commercial portfolio includes the first and only FDA-approved treatments for Parkinson’s disease psychosis and Rett syndrome. We are developing the next wave of therapeutic advancements with a robust and diverse pipeline that includes mid- to late-stage programs in Alzheimer’s disease psychosis and Lewy body dementia psychosis, along with earlier-stage programs that address other underserved patient needs. At Acadia, we’re here to be their difference. For more information, visit us at acadia.com and follow us on LinkedIn and X.
An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
You have made too many password recovery requests. Please try again tomorrow.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, to receive support.
